Photochemotherapy

Clinics in Dermatology

Volumn 15, Issue 5, 1997, Pages 769-780

  Lauharanta, Jorma ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BERGAPTEN; CYCLOSPORIN; DNA; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ETRETIN; FUROCOUMARIN DERIVATIVE; GERALEN; METHOTREXATE; METHOXSALEN; PSORALEN; RETINOID; TRIOXYSALEN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

CANCER RISK; CLINICAL TRIAL; CROSS LINKING; DRUG ABSORPTION; DRUG MECHANISM; ERYTHEMA; HUMAN; HYPERPIGMENTATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PHOTOCHEMOTHERAPY; PRIORITY JOURNAL; PRURITUS; PSORIASIS; PUVA; RELAPSE; REVIEW; SKIN CANCER; TELANGIECTASIA; TOPICAL DRUG ADMINISTRATION;

EID: 0030798661     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-081X(97)00015-1     Document Type: Article

References (52)

1. Berne B, Fischer T, Michaelsson G, et al. Long-term safety of trioxalen bath PUVA treatment: an 8-year follow-up study of 149 psoriasis patients. Photodermatol 1984;1:18-22.
2. Lindelöf B, Sigurgeirsson B, Tegner E, et al. PUVA and cancer: a large-scale epidemiological study. Lancet 1991;338:91-3.
3. Lindelöf B, Sigurgeirsson B, Tegner E, et al. Comparison of the carcinogenic potential of trioxsalen bath PUVA and oral methoxalen PUVA. A preliminary report. Arch Dermatol 1992;128:1341-4.
4. Hannuksela A, Pukkala E, Hannuksela M, et al. Cancer incidence among Finnish patients with psoriasis treated with trioxsalen bath PUVA. J Am Acad Dermatol 1996;35:685-9.
5. Vallat VP, Gilleaudeau P, Bartat L, et al. PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy. J Exp Med 1994;180:283-96.
6. Urano K, Matsuyama T, Urano R, et al. PUVA suppresses the expression of cell adhesion molecules of lymphocytes. Exp Dermatol 1995;4:36-41.
7. Morison WL. In vivo effects of psoralens plus longwave ultraviolet radiation on immunity. Natl Cancer Inst Monogr 1984;66:243-6.
8. Johnson R, Staiano-Coico L, Austin L, et al. PUVA-treatment selectively induces a cell cycle block and subsequent apoptosis in human T-lymphocytes. Photochem Photobiol 1996;63:566-71.
9. Kripke M, Morison W, Parrish J. Systemic suppression of contact hypersensitivity in mice by psoralen plus UVA radiation (PUVA). J Invest Dermatol 1983;81:87-92.
10. Koulu LM, Jansen CT. Antipsoriatic, erythematogenic and Langerhans cell marker depleting effect of bath-psoralens plus ultraviolet A treatment. Comparison of 8-methoxypsoralen and trimethylpsoralen photosensitization. J Am Acad Dermatol 1988;18:1053-9.
11. Ternowitz T. The enhanced monocyte and neutrophil chemotaxis in psoriasis is normalized after treatment with psoralens plus ultraviolet A and anthralin. J Am Acad Dermatol 1987;16:1169-75.
12. Minzuno N, Enami H, Esaki K. Effects of 8-methoxypsoralen plus UVA on psoriasis leukotactic factor. J Invest Dermatol 1979;72:64-6.
13. Chang A, Alkemade J, van de Kerkhof P. PUVA and UVB inhibit the intraepidermal accumulation of polymorphonuclear leukocytes. Br J Dermatol 1988;119:281-7.
14. Laing T, Richardson B, Toth M, et al. Ultraviolet light and 8-methoxypsoralen inhibit expression of endothelial adhesion molecules. J Rheumatol 1995;22:2126-31.
15. Larmi E. PUVA treatment inhibits nonimmunologic immediate contact reactions to benzoic acid and methyl nicotinate. Int J Dermatol 1989;28:609-11.
16. Brücke J, Tanew A, Ortel B, et al. Relative efficacy of 335 and 365 nm radiation in photochemotherapy of psoriasis. Br J Dermatol 1991;124:372-4.
17. Lauharanta J, Juvakoski T, Kanerva L, et al. Pharmacokinetics of 8-methoxypsoralen in serum and suction blister fluid. Arch Dermatol Res 1982;73:111-4.
18. Bonnot D, Beani JC, Boitard M, et al. Determination of 8-methoxypsoralen kinetics: a relevant factor in the treatment of psoriasis by psoralen plus ultraviolet A therapy. Photodermatol Photoimmunol Photomed 1994;10:33-7.
19. Tanew A, Ortel B, Rappersberger K, et al. 5-methoxypsoralen (Bergapten) for photochemotherapy. J Am Acad Dermatol 1988;18:333-8.
20. Wulf H. Aspects of the toxicology of 8-methoxypsoralen and long-wave ultraviolet light. Acta Derm Venereol Suppl (Stockh) 1982;106:1-42.
21. Sakuntabhai A, Diffey BL, Farr PM. Calculation of 8-methoxypsoralen dose according to body surface area in PUVA treatment. Br J Dermatol 1995;133:919-23.
22. Kammerau B, Klebe U, Zesch A, et al. Penetration, permeation and resorption of 8-methoxypsoralen. Comparative in vitro and in vivo studies after topical application of four standard preparations. Arch Dermatol Res 1976;255:31-42.
23. Neild V, Scott L. Plasma levels of 8-methoxypsoralen in psoriatic patients receiving topical 8-methoxypsoralen. Br J Dermatol 1982;106:199-203.
24. Gomez MI, Azana JM, Arranz I, et al. Plasma levels of 8-methoxypsoralen (8-MOP) after bath PUVA for psoriasis: relationship to disease severity. Br J Dermatol 1995;133:37-40.
25. Väätäinen N, Taskinen J. Penetration of trioxsalen into skin from trioxsalen bath. Arch Dermatol Res 1981;270:157-8.
26. Salo O, Lassus A, Taskinen J. Trioxsalen bath plus UVA treatment of psoriasis. Plasma concentration of the drug and clinical results. Acta Derm Venereol (Stockh) 1981;60:177-9.
27. Lowe N, Weingarten D, Bourget T, et al. PUVA therapy for psoriasis: comparison of oral and bath-water delivery of 8-methoxypsoralen. J Am Acad Dermatol 1986;14:754-60.
28. Turjanmaa K, Salo H, Reunala T. Comparison of trioxsalen bath and oral methoxsalen PUVA in psoriasis. Acta Derm Venereol (Stockh) 1984;65:86-8.
29. Hannuksela M, Karvonen J. Trioxsalen bath plus UVA effective and safe in the treatment of psoriasis. Br J Dermatol 1978;99:703-7.
30. Lawrence C, Marks J, Parker S, et al. A comparison of PUVA-etretinate and PUVA-placebo for palmoplantar pustular psoriasis. Br J Dermatol 1984;! 10:221-6.
31. Henseler T, Wolff K, Hönigsmann H, et al. Oral 8-methoxypsoralen photochemotherapy of psoriasis. The European PUVA study: a cooperative study among 18 European centres. Lancet 1981;1:853-7.
32. Wolff K, Hönigsmann H. Clinical aspects of photochemotherapy. Pharmacol Ther 1981;12:381-418.
33. Melski J, Tanenbaum L, Parrish JA, et al. Oral methoxsalen photochemotherapy for the treatment of psoriasis: a cooperative clinical trial. J Invest Dermatol 1977;68:328-35.
34. Lauharanta J, Juvakoski T, Lassus A. A clinical evaluation of the effects of an aromatic retinoid (Tigason), combination of retinoid and PUVA, and PUVA alone in severe psoriasis. Br J Dermatol 1981;104:325-32.
35. Berg M, Ros AM. Treatment of psoriasis with psoralens and ultraviolet A. A double-blind comparison on 8-methoxypsoralen and 5-methoxypsoralen. Photodermatol Photoimmunol Photomed 1994;10:217-20.
36. Calzavara-Pinton PG, Ortel B, Hönigsmann H, et al. Safety and effectiveness of an aggressive and individualized bath-PUVA regimen in the treatment of psoriasis. Dermatology 1994;189:256-9.
37. Lauharanta J, Geiger J-M. A double-blind comparison of acitretin and etretinate in combination with bath PUVA in the treatment of extensive psoriasis. Br J Dermatol 1989;121:107-12.
38. Wolff K. PUVA Klinik und Praxis. In: Braun-Falco O, Wolff H, editors. Fortschritte der praktischen Dermatologie und Venereologie. Bd 9. Berlin-Heidelberg: Springer Verlag, 1979:129-38.
39. Weinstein GD, White GM. An approach of the treatment of moderate to severe psoriasis with rotational therapy. J Am Acad Dermatol 1993;28:454-9.
40. Bruynzeel I, Bergman W, Hartevelt H, et al. High single-dose European PUVA-regimen also causes an excess of non-melanoma skin cancer. Br J Dermatol 1991;124:49-55.
41. Chuang TY, Heinrich LA, Schultz MD, et al. PUVA and skin cancer. A historical cohort study on 492 patients. J Am Acad Dermatol 1992;26:173-7.
42. Kanerva L, Niemi K-M, Lauharanta J. A semiquantitative light and electron microscopic analysis of histopathologic changes in photochemotherapy-induced freckles. Arch Dermatol Res 1984;276:2-11.
43. Niemi K-M, Niemi A, Kanerva L. Morphological changes in epidermis of PUVA-treated psoriasis patients with or withoutarsenic therapy. Arch Dermatol 1983;119:904-09.
44. Stern R, Lange R, and member of the photochemotherapy follow-up study. Non-melanoma skin cancer occurring in patients treated with PUVA five to ten years after first treatment. J Invest Dermatol 1988;91:120-4.
45. Hannuksela M, Stenbäck F, Lahti A. The carcinogenic properties of topical PUVA: a lifelong study in mice. Arch Dermatol Res 1986;278:347-51.
46. Gunther E, Yeasky T, Gasparro F, et al. Mutagenesis by 8-methoxypsoralen and 5-methylangelicin photoadducts in mouse fibroblasts: mutations at cross-linkable sites induced by monoadducts as well as cross-links. Cancer Res 1995;55:1283-8.
47. Cloud T, Hakim R, Griffin A. Photosensitization of the eye with methoxsalen. Arch Opthalmol 1961;66:689-94.
48. Parrish J, Chylack L, Woehler M, et al. Dermatological and ocular examinations in rabbits chronically photosensitized with methoxsalen. J Invest Dermatol 1979;73:250-5.
49. Lerman S, Borkman R. A method for detecting 8-methoxypsoralen in the ocular lens. Science 1977;197:1287-8.
50. Bäck O, Hollström E, Liden S, et al. Absence of cataract ten years after treatment with 8-methoxypsoralen. Acta Derm Venereol (Stockh) 1980;60:79-80.
51. Calzavara-Pinton PG, Carlino A, Manfredi E, et al. Ocular side effects of PUVA-treated patients refusing eye sun protection. Acta Derm Venereol Suppl (Stockh) 1994;186:164-5.
52. Cox N, Jones S, Downey D, et al. Cutaneous and ocular side-effects of oral photochemotherapy: results of an 8-year follow-up study. Br J Dermatol 1987;116:145-52.